Kevin Appelbaum Biography and Net Worth

CEO of Better Therapeutics

Kevin Appelbaum has been an entrepreneur for more than 25 years, often using digital technology to transform consumer and healthcare businesses. Most recently, he led Tria Beauty, the first company to make regulated medical laser technologies accessible to consumers for home-use, from preclinical to global commercial operations. During his tenure, the company received its first, and four subsequent FDA 510(k) clearances across three indications. Earlier in his career, he led the digital transformation of Sephora, a multi-billion-dollar retailer, and led businesses at Procter & Gamble and PepsiCo. His first startup was a joint venture with The Culinary Institute of America, focused on improving food literacy and healthy eating behaviors. Mr. Appelbaum has a B.S.E. in Chemical Engineering from the University of Pennsylvania, where he was a distinguished military graduate. Following graduation, he served peacetime and combat assignments as an officer in the U.S. Army Rangers.

What is Kevin J. Appelbaum's net worth?: The estimated net worth of Kevin J. Appelbaum is at least $0.00 as of March 31st, 2022. Mr. Appelbaum owns 6,250 shares of Better Therapeutics stock worth more than $0 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Appelbaum may own. Learn More about Kevin J. Appelbaum's net worth.
How do I contact Kevin J. Appelbaum?: The corporate mailing address for Mr. Appelbaum and other Better Therapeutics executives is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. Better Therapeutics can also be reached via phone at 415-887-2311 and via email at [email protected]. Learn More on Kevin J. Appelbaum's contact information.
Has Kevin J. Appelbaum been buying or selling shares of Better Therapeutics?: Kevin J. Appelbaum has not been actively trading shares of Better Therapeutics over the course of the past ninety days. Most recently, on Thursday, March 31st, Kevin J. Appelbaum bought 2,500 shares of Better Therapeutics stock. The stock was acquired at an average cost of $1.97 per share, with a total value of $4,925.00. Following the completion of the transaction, the chief executive officer now directly owns 6,250 shares of the company's stock, valued at $12,312.50. Learn More on Kevin J. Appelbaum's trading history.
Who are Better Therapeutics' active insiders?: Better Therapeutics' insider roster includes Kevin Appelbaum (CEO), Andrew Armanino (Director), Elder Granger (Director), Mark Heinen (Insider), and Risa Lavizzo-Mourey (Director). Learn More on Better Therapeutics' active insiders.

Kevin J. Appelbaum Insider Trading History at Better Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2022	Buy	2,500	$1.97	$4,925.00	6,250
12/20/2021	Buy	1,000	$4.60	$4,600.00
12/15/2021	Buy	750	$4.71	$3,532.50
12/10/2021	Buy	1,000	$5.98	$5,980.00
12/2/2021	Buy	500	$6.84	$3,420.00

Kevin J. Appelbaum Buying and Selling Activity at Better Therapeutics

Better Therapeutics Company Overview

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

2,000 shs

Average Volume

2,449,991 shs

Market Capitalization

$5,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.